Skip to main content

The Computational, Organoid, and Microphysiological Systems Initiative

Mark Miedel, PhD

Mark Miedel, PhD

Liver MPS platforms for MASLD/MASH and cancer drug screening

Contact mmiedel@pitt.edu

Technology Expertise

  • Liver MPS platforms with primary and iPSC-derived cells
  • Disease modeling with liver MPS including MASLD/MASH and liver metastatic niche
  • Organoid/MPS as drug screening platforms

Disease Focus

  • MASLD/MASH
  • Various Cancer Types